NanoViricidesNNVC
NNVC
About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Employees: 7
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,150% more call options, than puts
Call options by funds: $75K | Put options by funds: $6K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
13% more funds holding
Funds holding: 32 [Q3] → 36 (+4) [Q4]
4% more capital invested
Capital invested by funds: $2.01M [Q3] → $2.09M (+$74.4K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.19% less ownership
Funds ownership: 11.35% [Q3] → 10.16% (-1.19%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NNVC.
Financial journalist opinion
Based on 6 articles about NNVC published over the past 30 days
Positive
Proactive Investors
1 day ago
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid rising concern over vaccine failure and the lack of effective treatments. The Shelton, Connecticut-based company said it has initiated animal efficacy studies to evaluate NV-387 as a treatment for measles, noting there are currently no approved antiviral drugs for the disease.
Neutral
Accesswire
1 day ago
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains its drug development strategy to combat important global viral threats.
Positive
Proactive Investors
1 week ago
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug NV-387 for treating Mpox, a step toward regulatory submission in a region where the disease continues to spread. The approval, granted by the National Ethics Committee for Health (CNES) under the DRC's Ministry of Public Health, clears the company to submit a full clinical trial application (CTA) for NV-387, NanoViricides said.
Neutral
Newsfile Corp
1 week ago
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Positive
Proactive Investors
2 weeks ago
NanoViricides advances measles drug development amid rising US cases
NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. The Shelton, Connecticut-based biotechnology firm said it has completed propagation of the measles virus in its biosafety level-2 virology lab and is preparing to conduct an animal model study to test its clinical-stage antiviral candidate NV-387.
Neutral
Accesswire
2 weeks ago
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith.
Positive
Proactive Investors
1 month ago
NanoViricides evaluating antiviral drug NV-387 for measles treatment
NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at present a completely missing link in the response to measles virus outbreak,” said Anil Diwan, executive chairman of NanoViricides.
Neutral
Accesswire
1 month ago
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has begun evaluation of its clinical drug NV-387 for the treatment of the Measles virus.
Positive
Proactive Investors
1 month ago
NanoViricides unaffected by US tariff turmoil, says CFO
NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company's progress developing broad-spectrum antiviral therapeutics and how its technology remains unaffected by global market turmoil. Vyas explained that NanoViricides, based in Shelton, Connecticut, conducts all its research and development in-house, making it immune to international tariff changes.
Positive
Proactive Investors
1 month ago
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.
Charts implemented using Lightweight Charts™